Tesamorelin (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH) studied for its ability to stimulate pulsatile growth hormone output from the pituitary. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published studies, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water produces a concentration of roughly 3.33 mg/mL (about 3,333 mcg/mL). At that fill, drawing 0.30 mL on a U-100 insulin syringe equals 30 units and delivers approximately 1 mg, so each 30-unit increment corresponds to one 1 mg step in the schedule.

Standard (Gradual) Titration Schedule

The standard schedule reflects the daily evening dosing used in the published clinical model. A single lower-dose lead-in week precedes the maintenance dose to ease into consistent administration.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, to limit foaming.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (~3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Supplies Needed

• Tesamorelin vials (10 mg): ~11 vials for an 8-week run; ~17 vials for a 12-week run; ~22 vials for a 16-week run at the 2 mg daily maintenance dose.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks — one fresh syringe per daily draw.
• Bacteriostatic water (10 mL): roughly 33–66 mL total, i.e. four to seven 10 mL bottles across an 8–16 week schedule.
• Alcohol swabs: two to three 100-count boxes (~112–224 swabs) cover an 8–16 week schedule.

Protocol Overview

• Research goal: model GHRH-driven stimulation of endogenous growth hormone and downstream IGF-1, with attention to visceral fat dynamics.
• Schedule: once-daily subcutaneous administration, typically in the evening, in the published model.
• Dose band: 1 mg lead-in advancing to 2 mg daily maintenance.
• Fill: 10 mg lyophilized, reconstituted to ~3.33 mg/mL with 3 mL diluent.
• Storage: 2–8 °C sealed; 2–8 °C once reconstituted, used within 7 days.

Dosing Protocol Notes

• Begin with the 1 mg lead-in for the first week, then hold the 2 mg maintenance dose thereafter.
• Keep administration on a fixed daily cadence, ideally at night, to mirror the pulsatile GH release studied in trials.
• Most published efficacy signals for visceral fat appear over a 3–6 month window of continuous daily dosing.
• Because the concentration is lower than typical GH-secretagogue vials, double-check the 60-unit (0.60 mL) draw for the 2 mg dose.

Storage Instructions

Keep sealed lyophilized vials at 2–8 °C (35.6–46.4 °F), protected from light; some newer formulations remain stable at 20–25 °C (68–77 °F). Once reconstituted with bacteriostatic water, refrigerate at 2–8 °C and use within about 7 days. Do not freeze the reconstituted solution and avoid freeze-thaw cycles, which degrade the peptide. Allow refrigerated solution to warm slightly before drawing.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Because the reconstituted shelf life is short (~7 days), reconstitute only what will be sampled within that window.
• Keep the vial out of direct light and return it to refrigeration promptly after each draw.
• Document each draw — date, volume, remaining material — for reproducibility.

How Tesamorelin Works

Tesamorelin is a synthetic analog of the first 44 amino acids of human growth hormone-releasing hormone, modified with a trans-3-hexenoyl group at the N-terminus to resist enzymatic breakdown and extend its activity. It binds GHRH receptors on the anterior pituitary and stimulates the natural, pulsatile secretion of growth hormone, which in turn raises circulating IGF-1. Because it amplifies an endogenous signalling axis rather than supplying growth hormone directly, the physiological feedback loops governing GH release remain comparatively intact in the published model.

Reported Benefits & Side Effects

Benefits observed in studies

• Meaningful reductions in visceral adipose tissue over a 3–6 month course.
• Improvements in lipid markers, with potential reductions in liver fat in fatty-liver contexts.
• Exploratory signals for cognitive function under ongoing investigation.
• Benefits generally sustained out to about 52 weeks of continued dosing in the literature.

Side effects reported

• Injection-site reactions such as redness, itching, pain or bruising.
• Musculoskeletal complaints — joint pain, muscle aches and mild peripheral edema.
• Occasional carpal-tunnel-type tingling or numbness.
• Metabolic shifts including raised IGF-1 and small increases in HbA1c in some subjects.

Supporting Lifestyle Factors (Research Context)

• Balanced, protein-forward nutrition consistent with the metabolic endpoints studied.
• Combined aerobic and resistance activity to support body-composition outcomes.
• Adequate sleep, since GH pulses are tied to nightly sleep cycles, plus standard hydration controls.

Injection Technique (Reference Only)

• Clean the vial stopper and the chosen site with alcohol and let both air-dry completely.
• Pinch a skinfold (abdomen at least two inches from the navel) and insert at 90° where fat is adequate, or 45° on leaner sites.
• Release the pinch, inject slowly, and wait two to three seconds before withdrawing the needle.
• Rotate sites systematically across the abdomen, thighs and upper arms, and dispose of sharps in an approved container.

References

Related Protocols